Market Overview

UPDATE: Canaccord Genuity Downgrades Vical Following Allovectin Failure

Related VICL
Why Vical (VICL) Might Be a Diamond in the Rough? - Tale of the Tape
Vical Announces Initiation of Phase 1/2 Trial of a Therapeutic HSV-2 Vaccine for Genital Herpes

In a report published Tuesday, Canaccord Genuity analyst Ritu Baral downgraded Vical (NASDAQ: VICL) from Buy to Hold, and lowered the price target from $7.00 to $1.40.

In the report, Canaccord Genuity noted, “Lowering to HOLD, $1.40 target on Allovectin Ph3 failure and program halt. We still see blockbuster potential for the Astellas-partnered CMV franchise (ASP0113, f.k.a. CymVectin; TransVax) given unmet need. Our $1.40 target is based on a pNPV analysis.”

Vical closed on Monday at $1.53.

Posted-In: Canaccord Genuity Ritu BaralAnalyst Color Downgrades Analyst Ratings

 

Most Popular

Related Articles (VICL)

Around the Web, We're Loving...

Partner Network

Get Benzinga's News Delivered Free